

Poliomyelitis - Pipeline Review, H2 2019

<https://marketpublishers.com/r/P3F81473620EN.html>

Date: December 2019

Pages: 88

Price: US\$ 2,000.00 (Single User License)

ID: P3F81473620EN

Abstracts

Poliomyelitis - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H2 2019, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 11, 5, 4, 3 and 3 respectively.

Similarly, the Universities portfolio in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 4, 3 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Poliomyelitis - Overview
- Poliomyelitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Poliomyelitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Poliomyelitis - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Bharat Biotech Ltd
- Biken Co Ltd
- Bilthoven Biologicals BV
- Biological E Ltd
- Biological Mimetics Inc
- Boryung Pharmaceutical Co Ltd
- CanSino Biologics Inc
- Cleveland BioLabs Inc
- GlaxoSmithKline Plc
- Grifols SA
- Johnson & Johnson
- KM Biologics Co Ltd
- LG Chem Ltd
- Micron Biomedical Inc
- Nanolek
- Panacea Biotec Ltd
- Sanofi Pasteur SA
- Serum Institute of India Ltd
- Shantha Biotechnics Pvt Ltd
- Wuhan Institute of Biological Products Co Ltd

Poliomyelitis - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B])

vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSB-017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-2348 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [serotype 2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [serotype 2] vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis [serotype PV3] (virus like particles) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine + rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poliomyelitis - Dormant Projects

Poliomyelitis - Discontinued Products

Poliomyelitis - Product Development Milestones

Featured News & Press Releases

Apr 16, 2019: Sinovac announces positive results from Phase III trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) published in the journal of Infectiou

May 21, 2018: A single-injection vaccine for the polio virus

Apr 19, 2018: Sinovac Announces Preliminary Results of Phase III Trial on sIPV

May 16, 2017: Bilthoven Biologicals will produce polio vaccine in Bohumil, Czech Republic

Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate

May 11, 2011: Sanofi Pasteur Launches Pentaxim In China

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Poliomyelitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019
Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2019
Poliomyelitis - Pipeline by Bharat Biotech Ltd, H2 2019
Poliomyelitis - Pipeline by Biken Co Ltd, H2 2019
Poliomyelitis - Pipeline by Bilthoven Biologicals BV, H2 2019
Poliomyelitis - Pipeline by Biological E Ltd, H2 2019
Poliomyelitis - Pipeline by Biological Mimetics Inc, H2 2019
Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2019
Poliomyelitis - Pipeline by CanSino Biologics Inc, H2 2019
Poliomyelitis - Pipeline by Cleveland BioLabs Inc, H2 2019
Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H2 2019
Poliomyelitis - Pipeline by Grifols SA, H2 2019
Poliomyelitis - Pipeline by Johnson & Johnson, H2 2019
Poliomyelitis - Pipeline by KM Biologics Co Ltd, H2 2019
Poliomyelitis - Pipeline by LG Chem Ltd, H2 2019
Poliomyelitis - Pipeline by Micron Biomedical Inc, H2 2019
Poliomyelitis - Pipeline by Nanolek, H2 2019
Poliomyelitis - Pipeline by Panacea Biotec Ltd, H2 2019
Poliomyelitis - Pipeline by Sanofi Pasteur SA, H2 2019
Poliomyelitis - Pipeline by Serum Institute of India Ltd, H2 2019
Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2019
Poliomyelitis - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2019
Poliomyelitis - Dormant Projects, H2 2019
Poliomyelitis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Poliomyelitis - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Poliomyelitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Bharat Biotech Ltd
Biken Co Ltd
Bilthoven Biologicals BV
Biological E Ltd
Biological Mimetics Inc
Boryung Pharmaceutical Co Ltd
CanSino Biologics Inc
Cleveland BioLabs Inc
GlaxoSmithKline Plc
Grifols SA
Johnson & Johnson
KM Biologics Co Ltd
LG Chem Ltd
Micron Biomedical Inc
Nanolek
Panacea Biotec Ltd
Sanofi Pasteur SA
Serum Institute of India Ltd
Shantha Biotechnics Pvt Ltd
Wuhan Institute of Biological Products Co Ltd

I would like to order

Product name: Poliomyelitis - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/P3F81473620EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3F81473620EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970